Krishna Institute of Medical Sciences pushed through an 11.9% increase in consolidated net profit to ₹75 crore for the second quarter, driven by aggressive volume expansion across its hospital network. Revenue from operations leaped 39.9% to ₹1,344 crore from ₹961 crore in the corresponding quarter last year. Topline growth outpaced expectations. But profitability took a direct hit from operating friction.
Earnings before interest, taxes, depreciation, and amortisation (EBITDA) climbed 27.5% to ₹260 crore from ₹204 crore a year earlier. Yet the company shed operating profitability—EBITDA margins slipped 180 basis points to 19.4% against 21.2% in the prior-year period. The contraction pointed to heavier overheads tied to ongoing integration work.
| Metric | Q2 Current Year | Q2 Prior Year | Change (YoY) |
|---|---|---|---|
| Revenue from Operations | ₹1,344 crore | ₹961 crore | +39.9% |
| EBITDA | ₹260 crore | ₹204 crore | +27.5% |
| EBITDA Margin | 19.4% | 21.2% | -180 bps |
| Consolidated Net Profit | ₹75 crore | ₹67 crore | +11.9% |
The corporate overhaul went beyond quarterly numbers. In a filing submitted to exchanges, the board approved the merger of wholly-owned subsidiary KIMS Hospitals Private Limited directly into the parent company, Krishna Institute of Medical Sciences Limited. The move strips out corporate redundancy.
Simultaneously, the healthcare chain expanded its geographic footprint into central Kerala. The board sanctioned an Operations and Management agreement between wholly-owned arm KIMS Swastha Private Limited and LOVR Institute of Medical Sciences Limited to run Westfort Hospital in Thrissur. The structure allows KIMS to deploy operational bandwidth and medical protocols without bearing upfront greenfield real estate exposure.
Leadership continuity anchored the rest of the board's docket. Directors cleared a fresh five-year term for Dr. Abhinay Bollineni as Director and Chief Executive Officer. They also renewed the mandate of founder Dr. Bhaskara Rao Bollineni as Chairman and Managing Director for five years—securing institutional sign-off for his tenure to continue beyond the age of 70.
KIMS shares closed at ₹745.35 on Wednesday, November 4. The stock has gained 20.98% year to date, outpacing broader defensive peers as investors price in steady regional bed additions.